After a record 2024 of authorized medicines compared to the previous year, 2025 is also set to confirm the long wave of new drugs, which, with the green light from the EMA (the European Medicines Agency), are set to improve the prospects for treatment, especially in oncology and neurology, although on the new Alzheimer's drugs there is a partial slowdown by the European agency following new data on efficacy and safety. Important news, among many to come, also for vaccines, such as the whooping cough vaccine for children and the vaccine that protects against Chikungunya. Also on the way is the new monoclonal that protects infants and children in the early months of life against the respiratory virus during the risk season. Also expected within the year is the green light for the first gene therapy against bladder cancer that does not respond to other treatments, and for other drugs against melanoma, lung cancer, and breast cancer. While 114 new drugs were approved by the European agency last year, including 53 containing new active substances, there are 112 new drugs under evaluation in the current year with an opinion expected by the end of the year, informs the “Horizon Scanning 2025” report just published by the Italian Medicines Agency.